[PDF][PDF] Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for …
IB Vergote, A Jimeno, F Joly, D Katsaros… - Journal of clinical …, 2014 - researchgate.net
Journal of clinical oncology, 2014•researchgate.net
Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of
Disease Progression After First-Line Page 1 Randomized Phase III Study of Erlotinib Versus
Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based
Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment
of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study Ignace B.
Vergote, Antonio Jimeno, Florence Joly, Dionyssios Katsaros, Corneel Coens, Evelyn …
Disease Progression After First-Line Page 1 Randomized Phase III Study of Erlotinib Versus
Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based
Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment
of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study Ignace B.
Vergote, Antonio Jimeno, Florence Joly, Dionyssios Katsaros, Corneel Coens, Evelyn …
Purpose
This trial evaluated the efficacy of maintenance erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, after first-line chemotherapy.
researchgate.net